Cancer drug delivery最新文献

{"title":"Tourniquet infusion chemotherapy for osseous malignant lesions.","authors":"C P Karakousis,&nbsp;U Rao,&nbsp;P Kanter,&nbsp;M Brecher","doi":"10.1089/cdd.1985.2.35","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.35","url":null,"abstract":"<p><p>Two patients with osseous malignant lesions were treated with the tourniquet infusion method. The first patient, with two metastatic lesions in the left femur resulting from a renal adenocarcinoma, had three courses of intra-arterial Adriamycin. Biopsies of these lesions showed that the distal lesion, which was perfused during each treatment, was histologically negative, whereas the proximal lesion, which was not perfused because of the position of the catheter, contained the viable tumor. The second patient, a 12-year-old girl with osteogenic sarcoma of the proximal portion of the right tibia, had three courses of intra-arterial chemotherapy with Adriamycin and cisplatinum, and then underwent open biopsy, which was histologically negative. Another open biopsy six months later was also histologically negative. She has normal use of her extremity and, at eleven months since the initiation of treatment, she remains disease free. The evaluation of the tourniquet infusion technique in greater numbers of patients with bone tumors under carefully controlled conditions, appears warranted.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 1","pages":"35-47"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14980060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of intracarotid etoposide on opening the blood-brain barrier.","authors":"M K Spigelman,&nbsp;R A Zappulla,&nbsp;J D Goldberg,&nbsp;S J Goldsmith,&nbsp;D Marotta,&nbsp;L I Malis,&nbsp;J F Holland","doi":"10.1089/cdd.1984.1.207","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.207","url":null,"abstract":"<p><p>The effect of an intracarotid artery infusion of etoposide on blood-brain barrier (BBB) integrity was investigated in a rat model system. The external carotid arteries of Sprague-Dawley rats were catheterized in a retrograde manner. Etoposide in a dose range from 3.0 mg/kg to 22.5 mg/kg was infused into the internal carotid artery by this technique. BBB disruption was evaluated qualitatively by the appearance in the infused hemisphere of the systemically administered dye Evans blue and quantitatively by the ratio of counts of the technetium-labeled chelate of diethylenetriaminepentaacetic acid (99mTc-DTPA) in the infused to the noninfused hemisphere. Evidence of increased BBB permeability was seen at all doses of etoposide. Degree of BBB disruption increased with increasing doses of etoposide. The intracarotid infusion and subsequent BBB disruption were well tolerated. Further clinical trials employing the intracarotid administration of etoposide should be cognizant of the potential for BBB disruption.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 3","pages":"207-11"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17460665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective therapy of metastasis. I. Quantitation of tumorigenic circulating and covert cancer cells disseminated from metastatic and nonmetastatic tumors.","authors":"D Glaves,&nbsp;E Mayhew","doi":"10.1089/cdd.1984.1.293","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.293","url":null,"abstract":"<p><p>To determine the potential efficacy of therapeutic agents and different drug delivery systems against metastases, it is necessary to develop methodologies that can assay the effects of treatment at each step of the metastatic process. This report presents quantitative studies on the total numbers and potential tumorigenicity of cancer cells in the circulation and also secondarily arrested in the lungs of mice following their spontaneous dissemination from methylcholanthrene-induced fibrosarcomas. MC1 fibrosarcomas rarely metastasize but MC2 fibrosarcomas frequently generate pulmonary metastases and it was found, using a combination of direct cancer cell isolation techniques and quantitative bioassays, that MC2 tumors released cancer cells into the bloodstream earlier and with greater frequency than MC1 fibrosarcomas. Also, although similar doses of radiolabeled MC1 and MC2 cells injected intravenously were cleared equally effectively following their arrest in the lung microvasculature, those MC2 cells that survived clearance processes had 10-fold greater lung colonization potential than MC1 cells. Therefore, these experimental systems can be used critically to evaluate the effects of therapeutic agents at individual stages of metastasis as an alternative to measuring their effects solely on solid tumors or the final incidence of metastases, which represents the net result of a number of sequential, complex interactions between cancer cells and the host.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 4","pages":"293-302"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.293","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17601459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled release of microquantities of macromolecules.","authors":"J Murray,&nbsp;L Brown,&nbsp;R Langer","doi":"10.1089/cdd.1984.1.119","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.119","url":null,"abstract":"<p><p>A technique for insuring the controlled release of small amounts of macromolecules such as polypeptides from polymeric delivery systems is described. We show that incorporation of albumin in milligram quantities into these delivery systems can facilitate the sustained release of nanogram or microgram quantities of a model macromolecule such as inulin. The albumin-containing controlled-release polymers did not cause inflammation or tissue damage in two commonly used assay sites for certain biological growth factors such as tumor angiogenesis stimulators and inhibitors--the chick chorioallantoic membrane (CAM) and the rabbit cornea. The method reported here should be particularly suited to the delivery of purified growth factors which are active and usually obtainable in microgram or smaller amounts.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 2","pages":"119-23"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17602479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of routes of administration of interferon in cancer: a review and a proposal.","authors":"V Bocci","doi":"10.1089/cdd.1984.1.337","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.337","url":null,"abstract":"<p><p>Interferons are endowed with antiviral and antitumoral activities; the latter particularly has attracted attention, even though it remains uncertain whether it is preferentially due to a direct antiproliferative effect or to enhancement of host-mediated immune responses. Unfortunately, interferons administered in pharmacological doses produce considerable toxicity that is dose-related and that may require cessation of therapy. The administration of interferon has been carried out mostly by intravenous and intramuscular routes. High serum interferon titers have been expected to correlate with therapeutic efficacy. However, there is no such correlation, and certainly interferon levels in the interstitial fluid of target or effector cells would be more critical and informative. Moreover, because they are rapidly filtered by the kidneys, high serum titers are accompanied by considerable renal loss. Thus, several factors, one of which may be the unsuitability of administration routes, may explain the modest therapeutic efficacy of interferon so far observed in cancer. It must be emphasized that interferons and other biological response modifiers are pharmacodynamically unique substances able to elicit unpredictable responses; effects of these drugs depend on the nutritional and metabolic status and immune responsiveness of the host rather than simply on their plasma levels. After reviewing possible routes of administration, a new one, the lymphatic route, appears of interest. The basic strategy is to shift most of the interferon into the lymph pool minimizing direct absorption into the blood. In this way, the lymph/plasma ratio of interferon concentration will resemble that observed during the physiological response and will be greater than 1. Most of the injected interferon will then interact with the lymphoid system, even though eventually it will slowly drain into the blood pool. If the therapeutic index can be shown to be improved in patients, facilitated lymphatic absorption could become a preferential route for the administration of biological response modifiers.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 4","pages":"337-51"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17152939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review.","authors":"L Helson","doi":"10.1089/cdd.1984.1.353","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.353","url":null,"abstract":"<p><p>A review of the pharmacological background and clinical activity of different Ca2+ channel blockers concerning reversal of anticancer drug resistance in tumors suggests that verapamil and trifluoperazine may be the most immediate candidates. Reversal of resistance to anthracyclines and vinca alkaloids originally observed in mouse experimental leukemia cell lines has now been extended to other animal cell lines and human tumors as well. Evidence is available that resistance to drugs of other classes such as dactinomycin, etoposide, and mitoxantrone can be reversed by various calcium channel blockers. Apart from enhancing retention of anticancer drugs in tumor cells, little is actually known of the mechanism(s) by which this phenomenon occurs. There is inconclusive evidence for the role of Ca2+ ions and Ca2+ channel receptors in the process, and, furthermore, there is no evidence that Ca2+ channel blocking activity per se is necessary for the reversal of drug resistance.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 4","pages":"353-61"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17167226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temperature-dependent drug release from large unilamellar liposomes.","authors":"R L Magin,&nbsp;M R Niesman","doi":"10.1089/cdd.1984.1.109","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.109","url":null,"abstract":"<p><p>The drug-release properties of large unilamellar liposomes were measured at temperatures near the lipid's phase-transition temperature. The liposomes were formed from a mixture of dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol (4:1 by weight) by the reverse-phase evaporation process. These liposomes captured 25-35% of the radiolabeled anticancer drug cytosine [3H]-1-beta-arabinofuranoside in their aqueous compartment. They were stable in serum below the lipid's phase-transition temperature of 41 degrees C. Complete drug release occurred within seconds after the liposomes reached a temperature of 43 degrees C in serum. Addition of cholesterol or phosphatidylglycerol to the liposomal membrane reduced the drug-release temperature and broadened the range of drug release. These results show that suspensions of large unilamellar liposomes can be made to encapsulate a therapeutically useful quantity of drug that is rapidly and completely released at 43 degrees C in serum.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 2","pages":"109-17"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17607910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination intracavitary chemotherapy for malignant pleural disease.","authors":"M Markman,&nbsp;S B Howell,&nbsp;M R Green","doi":"10.1089/cdd.1984.1.333","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.333","url":null,"abstract":"<p><p>Seven previously heavily pretreated patients with malignant pleural disease and effusions were treated with 12 courses of combination intrapleural chemotherapy with cisplatin, cytarabine, and doxorubicin. Two patients with ovarian cancer metastatic to the pleura demonstrated dramatic clinical improvement following therapy. Local pain, nephrotoxicity, or bone marrow suppression were not observed during this trial. Further investigation of intrapleural therapy utilizing an escalated dose of cytarabine is warranted.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 4","pages":"333-6"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17601226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose alkylating agent therapy: a review of clinical experiences.","authors":"M A Cornbleet,&nbsp;R C Leonard,&nbsp;J F Smyth","doi":"10.1089/cdd.1984.1.227","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.227","url":null,"abstract":"","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 3","pages":"227-38"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.227","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17460666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and use of monoclonal antibodies in the treatment of cancer.","authors":"R B Bankert","doi":"10.1089/cdd.1984.1.251","DOIUrl":"https://doi.org/10.1089/cdd.1984.1.251","url":null,"abstract":"","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"1 3","pages":"251-67"},"PeriodicalIF":0.0,"publicationDate":"1984-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1984.1.251","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17460668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}